Adoptive cell therapy with young T cells
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsMark E. Dudley, Steven A. Rosenberg
Life of this patent
Estimating the term…
Abstract
The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted.
Claims22
A method of promoting regression of a cancer in a mammal comprising:
- (i) culturing autologous T cells;
- (ii) expanding the cultured T cells using OKT3 antibody, IL-2, and feeder lymphocytes, wherein the cultured T cells are enriched for CD8+ T cells prior to expansion of the T cells;
- (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy;
- and
- (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted.
A method of promoting regression of a cancer in a mammal comprising:
- (i) culturing autologous T cells;
- (ii) expanding the cultured T cells using OKT3 antibody, IL-2, and feeder lymphocytes, wherein the cultured T cells are enriched for CD8+ T cells prior to expansion of the T cells;
- (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy;
- and
- (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 29 days old, whereupon the regression of the cancer in the mammal is promoted.
Dependencies are inferred from the claim text.